KN035 for dMMR/MSI-H Advanced Solid Tumors

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy. For colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.

Trial Details

NCT ID
NCT03667170
Phase
PHASE2
Sponsor
3D Medicines (Sichuan) Co., Ltd.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • KN035
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically confirmed locally advanced or metastatic colorectal carcinoma or other malignant solid tumors.
  • Confirmed MMR deficient or MSI-H status.
  • At least one measureable lesion.
  • Eastern Cooperative Oncology Group performance status of 0 or 1 .

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →